Optimization of a method to reduce expression of progerin, the cause of HGPS (Pro

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$372,089.00
Award Year:
2010
Program:
SBIR
Phase:
Phase I
Contract:
1R43AG035451-01
Award Id:
95699
Agency Tracking Number:
AG035451
Solicitation Year:
n/a
Solicitation Topic Code:
NIA
Solicitation Number:
n/a
Small Business Information
RETROTHERAPY, LLC, 4519 GRETNA ST, BETHESDA, MD, 20814
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
145949066
Principal Investigator:
LLOYD MITCHELL
(301) 503-1202
LGM@RETROTHERAPY.BIZ
Business Contact:
GEORGE MITCHELL
() -
lgm@retrotherapy.biz
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): This proposal seeks to develop a specific and efficient means to reduce or eliminate the production of the progerin protein, the cause of the premature aging disease Hutchinson-Gilford Progeria Syndrome (HGPS). A de no vo point mutation in codon 608 of the lamin A/C gene is present in nearly all cases of HGPS. This dominant gain-of-function mutation alters the processing of lamin A pre-mRNA and leads to the production of progerin. We have demonstrated the feasibility of this new approach that alters the processing of lamin A. The goal of this proposal is to produce and test a large library of candidate molecules for their ability to alter lamin A processing in the context of a marker gene. A small number of candidate mole cules that most efficiently alter the production of the marker will be selected and tested individually in HGPS patient-derived cells. From these, a few lead candidate molecules that most specifically and efficiently reduce the production of progerin will be selected for further evaluation in Phase II if the results warrant continuation. PUBLIC HEALTH RELEVANCE: Children with Hutchinson-Gilford Progeria Syndrome suffer from many of the symptoms associated with normal physiologic aging. Death, usuall y from stroke or heart attack, occurs at a mean age of 13. At present, there is no treatment for this gain-of-function dominant mutation, although there are a number of approaches currently under investigation.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government